$IPAR

Inter Parfums (IPAR) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss

Inter Parfums (IPAR) reported Q2 2026 revenue of $341 million, up 2.1% but below the $345.8 million estimate. Gross profit rose to $223.5 million, while operating profit fell 17.3% to $48.9 million. Net income fell 4.7% to $30.5 million and diluted EPS was $0.95. Cash from operations was $45.6 million.

Original reporting
Published Aug 4, 2026, 8:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Inter Parfums (IPAR) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss — source image
Decision brief

The 30-second read

$IPARBearishMed
01

Why it matters

Traders can use the reported margin deterioration (operating profit down 17.3%, cost of sales up 4.1%) to reassess near-term earnings power and likely revision direction, while cash flow strength may moderate the narrative.

02

Market read

Earnings print is the primary catalyst: revenue and EPS both missed, operating profit fell sharply, but operating cash flow improved.

03

What to watch

The article does not break out segment performance, brand momentum, or guidance, so the market may overreact to the EPS miss without knowing whether it is temporary (timing, mix, or one-offs).

Relevance 8/10Novelty 7/10Timing: post-market today, after Q2 2026 earnings release

Background

Inter Parfums’ Q2 2026 results include a revenue miss versus consensus, operating profit decline, and an EPS miss, alongside stronger cash generation.

Company-level read

Ticker impact

$IPARBearishMedium confidence
Context

Inter Parfums reported Q2 2026 revenue of $341M (+2.1% YoY) but missed the $345.8M estimate, with diluted EPS of $0.95 also below expectations.

Expected impact

Likely downside bias for the next few sessions unless management commentary offsets the EPS and operating profit decline.

Evidence & confidence

Operating profit fell 17.3% to $48.9M and cost of sales rose 4.1%, while cash from operations improved. That mix typically weighs on earnings revisions despite better cash generation.

Market effects

Signals continued margin sensitivity in fragrance/cosmetics peers, with investors likely to scrutinize gross margin and operating leverage.

No specific regional demand signal provided beyond reported results.

Limited; this is company-specific earnings information without broader macro or industry catalyst.

Counterpoint

Improved operating cash flow and low capex could support buybacks or debt reduction, potentially cushioning the earnings miss.

Key entities

  • Inter Parfums, Inc.

    Reported Q2 2026 revenue, operating profit, net income, EPS, and cash flow figures.

  • Jean Madar

    CEO sold 20,000 shares on the open market in the past six months per the article.

Related articles

$IPARMed

Inter Parfums (NASDAQ:IPAR) Posts Better

Inter Parfums (NASDAQ:IPAR) reported Q2 CY2026 revenue of $341 million, up 2.1% year on year and 0.6% above market expectations, according to the company. Full-year revenue guidance was $1.48 billion at the midpoint, 1.5% below analysts’ estimates. GAAP EPS was $0.95, 2.1% below consensus. The stock was flat at $128.43 after results.

$IPARMed

INTERPARFUMS INC (IPAR): Results of Operations and Financial Condition

INTERPARFUMS INC (IPAR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 7 ex991_1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE INTERPARFUMS, INC. REPORTS 2026 SECOND QUARTER NET SALES 2026 Second Quarter Conference Call Scheduled for August 5, 2026 New York, New York, July 22, 2026, Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums”

$NVDAMed

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Broadcom, Microsoft, IBM, Meta, Tyson Foods & more

Wall Street analysts issued multiple calls Monday. Goldman initiated HawkEye 360 as buy; Morgan Stanley upgraded Dell to equal weight; Wells Fargo upgraded Tandem Diabetes Care to overweight. Citizens initiated Microsoft at Market Outperform with a $550 target; Barclays initiated IBM at overweight with a $350 target. Cantor reiterated Tesla overweight; RBC reiterated Meta outperform. Broadcom was reiterated overweight by Morgan Stanley, raising its target to $485.

$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.